Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups : Episode 7

Emerging Data on Oral SERDS

November 25, 2024

By Rahul Gosain, MD
Rohit Gosain, MD

Opinion

Video

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective estrogen receptor degraders (SERDs), including elacestrant, highlighting trials exploring its combination with other therapies and its potential in different patient populations.

EP: 1.Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

EP: 2.Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1m with other alterations

EP: 4.Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease

EP: 5.Elacestrant: Clinical Pearls for AE Management

EP: 6.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

Now Viewing

EP: 7.Emerging Data on Oral SERDS

What are some ongoing studies investigating novel uses of oral SERDs, including those of elacestrant?

Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.